Online inquiry

IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8332MR)

This product GTTS-WQ8332MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets TFRC gene. The antibody can be applied in Glioblastoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Corynebacterium diphtheriae; Homo sapiens
RefSeq NM_001128148.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7037
UniProt ID P02786
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8332MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14474MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA RO-7105705
GTTS-WQ12020MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MM-302
GTTS-WQ11870MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MLN-0264
GTTS-WQ4111MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BI-204
GTTS-WQ1790MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-402
GTTS-WQ11161MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MDX-1333
GTTS-WQ10843MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA M9346A
GTTS-WQ3745MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY-1093884
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW